Farmako Healthcare vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
Farmako Healthcare logo

Farmako Healthcare

EmergingHealthcare

General

Bengaluru 30-minute medicine delivery with digital health records and chronic care management; YC W20 $3.1M at ₹10.7Cr revenue with 36% CAGR competing with PharmEasy and 1mg for India pharmacy delivery.

AI VisibilityBeta
Overall Score
D39
Category Rank
#403 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
35
Gemini
38

About

Farmako Healthcare is a Bengaluru-based healthtech platform — backed by Y Combinator (W20) and HOF Capital with $3.1 million raised including a $1.6 million round in August 2024 and a pre-Series A in June 2025 — providing ultra-fast medicine delivery (30-minute delivery within service areas), digital health records management, and personalized health insights for patients managing chronic conditions and routine pharmacy needs in Indian metros. Founded in 2019 and generating ₹10.7 crore (approximately $1.3 million USD) in annual revenue as of March 2024 with 36% revenue CAGR and a 63-person team, Farmako serves the medication adherence and pharmacy access market in India's urban health ecosystem.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#403
Category Rank
#2
87
AI Consensus
83
stable
Trend
stable
36
ChatGPT
92
35
Perplexity
93
38
Gemini
89
39
Claude
96
40
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.